Assessing the impact of evolving evidence in renal cell carcinoma treatment: An update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT) |
| |
| Affiliation: | 1. Department of Oncology, The Royal Marsden Hospital, Fulham Rd, London SW3 6JJ, UK;2. Department of Medical Oncology, University Hospital del Mar-IMIM, Barcelona, Spain;3. Department of Oncology, Cambridge University Health Partners, Cambridge, UK;4. Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France;5. Center of Operative Urology Bremen, Bremen, Germany;6. Department of Urology, Paris XI Bicetre University Hospital, Paris, France;7. Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, San Matteo University Hospital Foundation, Pavia, Italy;8. Department of Medical Oncology, Hôpital Saint André, Bordeaux University Hospital, Bordeaux, France;9. Department of Medicine I, Clinical Division of Oncology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria;10. Department of General Medical Oncology and Laboratory of Experimental Oncology, University Hospitals Leuven, Catholic University Leuven, Leuven, Belgium;11. Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy;12. Department of Oncology, Military Medical Institute, Warsaw, Poland;13. Double Helix Consulting, London, UK;1. Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 121 (7th Floor), 1000 Brussels, Belgium;2. Research Center of Epidemiology, Biostatistics and Clinical Research, School of Public Health, Université Libre de Bruxelles, Campus Erasme – CP598, Route de Lennik 808, 1070 Brussels, Belgium;3. Department of Medical Oncology, Hirslanden Clinic Aarau, Schänisweg, 5001 Aarau, Switzerland;4. Research Center of Social Approaches of Health, School of Public Health, Université Libre de Bruxelles, Campus Erasme – CP 596, Route de Lennik, 808, 1070 Brussels, Belgium;5. Breast International Group Headquarters (BIG-aisbl), Brussels, Belgium;1. Gastrointestinal Oncology Department, Gustave Roussy Institute, Villejuif, France;2. Faculté de Médecine, Paris Sud Uiversty Le Kremlin Bicêtre, France;3. Gastrointestinal Oncology Department, La Timone Hospital, Aix-Marseille Université, Marseille, France;4. Medical Oncology Department, Saint-André Hospital, Bordeaux, France;5. Clinical Medicine and Gastroenterology Department, St James’s Hospital and Trinity College, Dublin, Ireland;6. Medical Oncology Department, Georges Pompidou European Hospital, Paris, France;7. Radio Diagnostic Department, Gustave Roussy Institute, Villejuif, France;8. Radiology Department, Beaujon Hospital, Clichy, France;9. Nuclear Medicine and Endocrine Oncology Department, Gustave Roussy Institute, Villejuif, France;10. Medical Oncology Department, Edouard Herriot Hospital, Lyon, France;11. Pathology Department, Edouard Herriot Hospital, Lyon, France;12. Clinial Operating Department, Roche Laboratories, Boulogne-Billancourt, France;13. Oncology Department, Roche Laboratories, Boulogne-Billancourt, France;14. Medical Oncology Department, Curie Institute, Paris, France;1. Medical Oncology Department, Curie Institute, Paris, France;2. Medical Oncology Department, Edouard Herriot Hospital, Lyon, France;3. Nuclear Medicine and Endocrine Oncology Department, Gustave Roussy Institute, Villejuif, France;4. Hematology and Oncology Department, University Hospital, Strasbourg, France;5. Gastroenterology and Pancreatology Department, Beaujon Hospital, Clichy, France;6. Hematology and Oncology Department, Oscar Lambret Center, Lille, France;7. Medical Oncology Department, Saint-Antoine Hospital, Bordeaux, France;8. Hepato-Gastroenterology and Digestive Oncology Department, Robert Debré Hospital, Reims, France;9. Radio Diagnostic Department, Gustave Roussy Institute, Villejuif, France;10. Laboratory of Translational Research, Gustave Roussy Institute, Villejuif, France;11. Hepato-Gastroenterology and Digestive Oncology Department, Georges Pompidou European Hospital, Université Paris V, Paris, France;12. Gastrointestinal Oncology Department, Gustave Roussy Institute, Villejuif, France;1. Department of Hematology, Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The Netherlands;2. Department of Biostatistics, Cancer Center Amsterdam (CCA), VU University Medical Center, Amsterdam, The Netherlands;1. Department of Hematology and Medical Oncology, Health Research Institute-INCLIVA, Valencia, Spain;2. Dermatology Unit, La Paz Hospital, Madrid, Spain;3. Dermatology Unit, Ramon y Cajal Hospital, Madrid, Spain;4. Dermatology Unit, Dr. Negrin Hospital, Gran Canaria, Spain;5. Department of Medicine, University Jaume I of Castellon, Castellon, Spain;1. Institute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Mianyang 621900, People’s Republic of China;2. State Key Laboratory of Functional Materials for Informatics and Nanotechnology Laboratory, Shanghai Institute of Micro-system and Information Technology, Chinese Academy of Sciences, Shanghai 200050, People’s Republic of China;3. Key Laboratory of Polar Materials and Devices, Ministry of Education, Department of Electronics, East China Normal University, Shanghai 200241, People’s Republic of China |
| |
| Abstract: | The appropriateness of the numerous therapeutic options available for patients with advanced or metastatic renal cell carcinoma (RCC) was evaluated in 2011, using the RAND/University of California, Los Angeles (UCLA) appropriateness methodology to match treatment suitability to a range of patient scenarios. However, the RCC therapeutic area evolves rapidly and a body of new clinical data has accrued in the intervening years; as a result the exercise was repeated in 2013 using the same methodology, expert panel and patient scenarios. The aim of the updated assessment was to update the guidance to clinicians and use it to develop an interactive web-based application, the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT).This round of assessment achieved greater concordance concerning the appropriateness of treatments/interventions for the clinical scenarios tested; this higher level of agreement is likely to reflect the body of scientific evidence accrued since the previous assessment exercise. Many of the areas of disagreement in 2011 related to the suitability of pazopanib or sunitinib treatment; in the 2013 assessment both agents were considered appropriate treatment options for many of the clinical scenarios assessed. Uncertain scenarios often are related to the optimal management of metastatic RCC with clear cell histology. The use of the RAND/UCLA RCC assessment findings to develop the ReCATT support tool will help to disseminate expert opinion concerning best treatment practice and guide the clinical management of RCC patients treated in the community setting. |
| |
| Keywords: | Renal cell carcinoma Advanced Metastatic Treatments Interventions |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
